New Long-Acting painkiller could cut opioid use after keyhole surgery

NCT ID NCT07458256

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a long-acting numbing drug (liposomal bupivacaine) plus standard bupivacaine works better than standard bupivacaine alone for pain after laparoscopic surgery. About 190 adults having gallbladder, hernia, or appendix surgery will receive one of the two treatments. The goal is to see if the combination reduces the need for rescue pain medication within 48 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

liposomal bupivacaine plus bupivacaine hydrochloride

What this could lead to

If it works, this could provide longer-lasting pain relief after laparoscopic surgery, reducing the need for opioid painkillers.

What could go wrong

This is a mid-sized trial (190 people) comparing two local anesthetics, so any benefit may be modest. Results may not apply to other surgeries or pain types.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCAL INFILTRATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tiantan Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100070, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••